Teladoc Inc. (NYSE:TDOC) VP Mark Hirschhorn sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $17.19, for a total value of $171,900.00. Following the completion of the transaction, the vice president now directly owns 258,387 shares of the company’s stock, valued at $4,441,672.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Mark Hirschhorn also recently made the following trade(s):

  • On Thursday, November 10th, Mark Hirschhorn sold 5,000 shares of Teladoc stock. The shares were sold at an average price of $17.50, for a total value of $87,500.00.
  • On Monday, October 17th, Mark Hirschhorn sold 5,000 shares of Teladoc stock. The shares were sold at an average price of $15.52, for a total value of $77,600.00.

Shares of Teladoc Inc. (NYSE:TDOC) opened at 17.70 on Tuesday. Teladoc Inc. has a one year low of $9.08 and a one year high of $22.00. The firm has a 50-day moving average price of $16.66 and a 200 day moving average price of $15.75. The stock’s market capitalization is $814.77 million.

Teladoc (NYSE:TDOC) last announced its earnings results on Thursday, October 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.03. Teladoc had a negative return on equity of 32.68% and a negative net margin of 69.15%. The company had revenue of $32.40 million for the quarter, compared to the consensus estimate of $32.29 million. During the same period last year, the business posted ($0.35) EPS. The company’s revenue was up 62.0% on a year-over-year basis. On average, equities analysts expect that Teladoc Inc. will post ($1.42) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Several research analysts have recently weighed in on TDOC shares. FBR & Co reaffirmed a “buy” rating on shares of Teladoc in a research note on Sunday, August 28th. Zacks Investment Research raised Teladoc from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Monday, July 25th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $21.00 target price (down from $22.00) on shares of Teladoc in a research note on Friday, August 5th. Chardan Capital started coverage on Teladoc in a research note on Wednesday, November 16th. They set a “buy” rating and a $24.00 target price for the company. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $24.00 target price (down from $25.00) on shares of Teladoc in a research note on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Teladoc presently has a consensus rating of “Buy” and a consensus target price of $22.91.

Several hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its stake in Teladoc by 77.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 370,066 shares of the company’s stock valued at $6,776,000 after buying an additional 161,316 shares in the last quarter. Credit Suisse AG boosted its stake in Teladoc by 4.3% in the third quarter. Credit Suisse AG now owns 12,055 shares of the company’s stock valued at $221,000 after buying an additional 498 shares in the last quarter. Jane Street Group LLC acquired a new stake in Teladoc during the third quarter valued at approximately $292,000. Capital World Investors boosted its stake in Teladoc by 186.7% in the third quarter. Capital World Investors now owns 3,295,269 shares of the company’s stock valued at $60,336,000 after buying an additional 2,146,021 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Teladoc during the third quarter valued at approximately $275,000. 41.23% of the stock is owned by institutional investors and hedge funds.

Teladoc Company Profile

Teladoc, Inc, together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

5 Day Chart for NYSE:TDOC

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.